JP2003528138A5 - - Google Patents

Download PDF

Info

Publication number
JP2003528138A5
JP2003528138A5 JP2001570255A JP2001570255A JP2003528138A5 JP 2003528138 A5 JP2003528138 A5 JP 2003528138A5 JP 2001570255 A JP2001570255 A JP 2001570255A JP 2001570255 A JP2001570255 A JP 2001570255A JP 2003528138 A5 JP2003528138 A5 JP 2003528138A5
Authority
JP
Japan
Prior art keywords
seq
hepatitis
compound
host
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001570255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528138A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/009987 external-priority patent/WO2001072294A2/en
Publication of JP2003528138A publication Critical patent/JP2003528138A/ja
Publication of JP2003528138A5 publication Critical patent/JP2003528138A5/ja
Withdrawn legal-status Critical Current

Links

JP2001570255A 2000-03-29 2001-03-29 デルタ肝炎ウイルス感染症の治療法 Withdrawn JP2003528138A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19313500P 2000-03-29 2000-03-29
US60/193,135 2000-03-29
PCT/US2001/009987 WO2001072294A2 (en) 2000-03-29 2001-03-29 Method of treating hepatitis delta viral infection

Publications (2)

Publication Number Publication Date
JP2003528138A JP2003528138A (ja) 2003-09-24
JP2003528138A5 true JP2003528138A5 (https=) 2008-05-08

Family

ID=22712393

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001570255A Withdrawn JP2003528138A (ja) 2000-03-29 2001-03-29 デルタ肝炎ウイルス感染症の治療法

Country Status (16)

Country Link
US (2) US6670342B2 (https=)
EP (1) EP1284720B1 (https=)
JP (1) JP2003528138A (https=)
KR (3) KR100893549B1 (https=)
CN (1) CN1268345C (https=)
AT (1) ATE339211T1 (https=)
AU (1) AU2001249564A1 (https=)
BR (1) BR0109716A (https=)
CA (1) CA2405502A1 (https=)
CY (1) CY1105768T1 (https=)
DE (1) DE60123042T2 (https=)
DK (1) DK1284720T3 (https=)
ES (1) ES2272460T3 (https=)
IL (1) IL151981A0 (https=)
PT (1) PT1284720E (https=)
WO (1) WO2001072294A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151981A0 (en) 2000-03-29 2003-04-10 Univ Georgetown Method of treating hepatitis delta viral infection
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
DE10346721A1 (de) * 2003-10-08 2005-05-04 Holger Kalthoff Oligonukleotide, diese enthaltende Mittel und deren Verwendung
US8642602B2 (en) * 2009-02-04 2014-02-04 University Of Georgia Research Foundation, Inc. Method of inhibiting fibrogenesis and treating fibrotic disease
AU2010319999B2 (en) * 2009-11-16 2014-01-16 University Of Georgia Research Foundation, Inc. 2'-Fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
AU2013308045B2 (en) 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections
EA039949B1 (ru) * 2012-09-21 2022-03-31 Репликор Инк. Способы лечения инфекций вирусом гепатита в и гепатита d
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN104694544A (zh) * 2015-03-24 2015-06-10 刘红卫 结合丁型肝炎病毒的核酸适配子及其应用
KR20170132327A (ko) * 2015-04-07 2017-12-01 스프링 뱅크 파마슈티칼스, 인크. Hbv 감염의 치료를 위한 조성물 및 방법
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
WO2017132332A1 (en) 2016-01-28 2017-08-03 Svenska Vaccinfabriken Produktion Ab Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes
CN106333960A (zh) * 2016-11-01 2017-01-18 侯建生 臭氧化油在肝病防治中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4093714A (en) 1974-03-15 1978-06-06 Icn Pharmaceuticals, Inc. 9β-D-Arabinofuranosylpurine nucleotides and method of use
US4210638A (en) 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
GB2060604B (en) 1979-10-03 1983-11-23 Univ Birmingham And Stichting E15-(2-halogenovinyl)-2'-deoxycytidines
US4468384A (en) 1982-01-05 1984-08-28 The Research Foundation Of State University Of New York Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3479158D1 (en) 1983-03-04 1989-08-31 Noctech Ltd Diagnostic agent, a process for its preparation and its use in diagnostic methods
US4666892A (en) 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
ES2061500T5 (es) 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
US5246924A (en) * 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
AU2526188A (en) 1987-09-22 1989-04-18 Regents Of The University Of California, The Liposomal nucleoside analogues for treating aids
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
EP0491077A1 (en) 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
EP0746319A4 (en) 1993-05-12 1997-11-05 Karl Y Hostetler ACYCLOVIR DERIVATIVES FOR TOPICAL USE
EP0702556B1 (en) 1993-06-10 2002-10-23 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5639647A (en) 1994-03-29 1997-06-17 Ribozyme Pharmaceuticals, Inc. 2'-deoxy-2'alkylnucleotide containing nucleic acid
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
AU6605196A (en) 1996-02-29 1997-09-16 Duke University Method of treating hepatitis delta virus infection
US5753789A (en) 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
DE19641034A1 (de) 1996-10-04 1998-04-09 Claussen Nils Pulverförmige Zubereitung von wasserempfindlichen anorganischen Substanzen, ihre Herstellung und Verwendung
IL151981A0 (en) * 2000-03-29 2003-04-10 Univ Georgetown Method of treating hepatitis delta viral infection
US6985662B2 (en) * 2003-10-30 2006-01-10 Corning Incorporated Dispersion compensating fiber for moderate dispersion NZDSF and transmission system utilizing same

Similar Documents

Publication Publication Date Title
JP2003528138A5 (https=)
JP7336191B2 (ja) Ｂ型肝炎ウイルス感染に対するＲＮＡｉ療法
TWI639432B (zh) 寡聚物及寡聚物結合物
TWI881004B (zh) 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合
JP2015211676A (ja) タンパク質発現用未修飾および修飾ヌクレオチドの組み合わせを有するｒｎａ
JP2015523853A (ja) Ａｔｐ２ａ２発現を調節するための組成物及び方法
JP2015518712A (ja) Ｍｅｃｐ２発現を調節するための組成物及び方法
JP2015523855A (ja) Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法
TW201408309A (zh) 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
AU2016219052B2 (en) Compositions and methods for modulating RNA
HK1231402A1 (zh) 治疗b型肝炎和d型肝炎病毒感染的方法
WO2018193902A1 (ja) マイクロｒｎａによるｂ型肝炎ウイルスに対する抗ウイルス効果
Loomba et al. Novel approaches to new therapies for hepatitis B virus infection
Manthey et al. In situ expression of transforming growth factor beta in streptococcal cell wall-induced granulomatous inflammation and hepatic fibrosis
Hartwig et al. Interferon-α stimulation of liver cells enhances hepatitis delta virus RNA editing in early infection
CN114729363A (zh) Il-34反义剂及其使用方法
WO2006038608A1 (ja) オリゴ二本鎖ｒｎａ及び医薬組成物
KR102685034B1 (ko) 금속 나노 입자-핵산 결합체를 기반으로 하는 유전자 운반체
CN119998457A (zh) 基于金属纳米颗粒-核酸缀合物的基因载体
JPH09507062A (ja) 抗ｂ型肝炎ウイルスオリゴヌクレオチド
CN119055636A (zh) 抑制hbv转录和乙肝表面抗原的化合物及其应用
WO2023150678A2 (en) Compositions and methods for the treatment of nonalcoholic steatohepatitis (nash) fibrosis
CN103127492A (zh) 一种抗丙型肝炎病毒的蛋白及其用途
CN120624481A (zh) Ddost和sec61a在调控乙肝病毒抗原表达和hbv复制中的应用
KR20250076429A (ko) 금속 나노 입자-핵산 결합체를 기반으로 하는 운반체를 포함하는 대사성 질환 치료제